MYCN and neuroblastoma: To further understand the cell state alterations in neuroblastoma resistance, we treated MYCN-amplified patient-derived xenografts (SJNB14) implanted subcutaneously into CB17/SCID mice with indisulam (25 mg/kg, 5 days on/2 days off for two weeks).